Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN) and IDEAYA Biosciences (IDYA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medline, Inc. Class A (MDLN – Research Report) and IDEAYA Biosciences (IDYA – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medline, Inc. Class A (MDLN)
Medline, Inc. Class A received a Buy rating and a $48.00 price target from Morgan Stanley analyst Patrick Wood today. The company’s shares closed last Friday at $40.52.
According to TipRanks.com, Wood is a 3-star analyst with an average return of
Currently, the analyst consensus on Medline, Inc. Class A is a Moderate Buy with an average price target of $48.00.
See the top stocks recommended by analysts >>
IDEAYA Biosciences (IDYA)
LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences today and set a price target of $62.00. The company’s shares closed last Friday at $37.38.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
Currently, the analyst consensus on IDEAYA Biosciences is a Strong Buy with an average price target of $49.86, implying a 35.3% upside from current levels. In a report issued on January 6, UBS also initiated coverage with a Buy rating on the stock with a $50.00 price target.
